scholarly journals Recent Advances in Ocular Nucleic Acid-Based Therapies: The Silent Era

10.5772/48454 ◽  
2012 ◽  
Author(s):  
Covadonga Paeda ◽  
Tamara Martnez ◽  
Natalia Wright ◽  
Ana Isabel
2020 ◽  
Vol 5 (1) ◽  
pp. 49-66 ◽  
Author(s):  
Léonard Bezinge ◽  
Akkapol Suea-Ngam ◽  
Andrew J. deMello ◽  
Chih-Jen Shih

This account reviews the major amplification strategies utilizing nanomaterials in electrochemical biosensing for robust and sensitive molecular diagnostics.


2020 ◽  
Vol 10 (2) ◽  
pp. 97-101 ◽  
Author(s):  
Minzhe Shen ◽  
Ying Zhou ◽  
Jiawei Ye ◽  
Abdu Ahmed Abdullah AL-maskri ◽  
Yu Kang ◽  
...  

2019 ◽  
Vol 55 (2) ◽  
pp. 86 ◽  
Author(s):  
Zirui Fu ◽  
Yi-Cheng Lu ◽  
James J. Lai
Keyword(s):  

2008 ◽  
Vol 18 (2) ◽  
pp. 185-193 ◽  
Author(s):  
Modesto Orozco ◽  
Agnes Noy ◽  
Alberto Pérez

Lab on a Chip ◽  
2016 ◽  
Vol 16 (5) ◽  
pp. 790-811 ◽  
Author(s):  
Sarah M. Friedrich ◽  
Helena C. Zec ◽  
Tza-Huei Wang

This review discusses recent advances in single molecule analysis of nucleic acid molecules within micro- and nano-fluidic environments.


2017 ◽  
Vol 38 (6) ◽  
pp. 798-805 ◽  
Author(s):  
Jun-chen Wu ◽  
Qing-chun Meng ◽  
Hong-mei Ren ◽  
Hong-tao Wang ◽  
Jie Wu ◽  
...  

2021 ◽  
Vol 2021 ◽  
pp. 1-21
Author(s):  
I. B. K. Thomas ◽  
K. A. P. Gaminda ◽  
C. D. Jayasinghe ◽  
D. T. Abeysinghe ◽  
R. Senthilnithy

The past few decades have witnessed a rapid evolution in cancer drug research which is aimed at developing active biological interventions to regulate cancer-specific molecular targets. Nucleic acid-based therapeutics, including ribozymes, antisense oligonucleotides, small interference RNA (siRNA), aptamer, and DNAzymes, have emerged as promising candidates regulating cancer-specific genes at either the transcriptional or posttranscriptional level. Gene-specific catalytic DNA molecules, or DNAzymes, have shown promise as a therapeutic intervention against cancer in various in vitro and in vivo models, expediting towards clinical applications. DNAzymes are single-stranded catalytic DNA that has not been observed in nature, and they are synthesized through in vitro selection processes from a large pool of random DNA libraries. The intrinsic properties of DNAzymes like small molecular weight, higher stability, excellent programmability, diversity, and low cost have brought them to the forefront of the nucleic acid-based therapeutic arsenal available for cancers. In recent years, considerable efforts have been undertaken to assess a variety of DNAzymes against different cancers. However, their therapeutic application is constrained by the low delivery efficiency, cellular uptake, and target detection within the tumour microenvironment. Thus, there is a pursuit to identify efficient delivery methods in vivo before the full potential of DNAzymes in cancer therapy is realized. In this light, a review of the recent advances in the use of DNAzymes against cancers in preclinical and clinical settings is valuable to understand its potential as effective cancer therapy. We have thus sought to firstly provide a brief overview of construction and recent improvements in the design of DNAzymes. Secondly, this review stipulates the efficacy, safety, and tolerability of DNAzymes developed against major hallmarks of cancers tested in preclinical and clinical settings. Lastly, the recent advances in DNAzyme delivery systems along with the challenges and prospects for the clinical application of DNAzymes as cancer therapy are also discussed.


2020 ◽  
Vol 47 (11) ◽  
pp. 9033-9041
Author(s):  
Pranav Kumar Prabhakar ◽  
Jyoti Lakhanpal

2004 ◽  
Vol 4 (3) ◽  
pp. 337-348 ◽  
Author(s):  
Violeta L Marin ◽  
Subhadeep Roy ◽  
Bruce A Armitage

Sign in / Sign up

Export Citation Format

Share Document